Lisanti Capital Growth LLC Grows Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Lisanti Capital Growth LLC grew its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 61.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 40,770 shares of the company’s stock after purchasing an additional 15,595 shares during the period. Lisanti Capital Growth LLC’s holdings in Amphastar Pharmaceuticals were worth $2,522,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 99.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after acquiring an additional 628 shares during the period. Covestor Ltd lifted its position in shares of Amphastar Pharmaceuticals by 859.0% during the 3rd quarter. Covestor Ltd now owns 1,966 shares of the company’s stock valued at $90,000 after acquiring an additional 1,761 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 115.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock valued at $150,000 after acquiring an additional 1,300 shares during the period. Finally, Annex Advisory Services LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $204,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Trading Up 0.5 %

AMPH traded up $0.22 during trading on Monday, hitting $42.68. The company’s stock had a trading volume of 209,637 shares, compared to its average volume of 442,491. The firm’s 50 day moving average price is $43.23 and its 200-day moving average price is $50.76. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. The stock has a market cap of $2.05 billion, a PE ratio of 16.54, a PEG ratio of 1.02 and a beta of 0.85. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.06 and a twelve month high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The business had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. On average, analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on AMPH shares. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. started coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $66.00.

Insider Activity

In related news, Director Michael A. Zasloff sold 12,500 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares of the company’s stock, valued at approximately $1,006,160.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 14,000 shares of company stock valued at $655,145 in the last ninety days. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.